Alpha-1 adrenergic receptors are present on vascular smooth muscle and myocardial tissue; therefore, stimulation causes vasoconstriction and positive inotropic effects, respectively. Higher acuity indications for alpha-1 receptor agonists include cases of vasodilatory shock, hypotension, and hypoperfusion. Often patients receiving an alpha-1 agonist are concurrently undergoing fluid resuscitation, for example, sepsis or septic shock, cardiopulmonary arrest, and heart failure decompensation. Other lower acuity indications for alpha-1 agonists would include glaucoma (to lower intraocular pressure) and the use of nasal decongestants. Nasal decongestive effects occur by the induction of local vasoconstrictive effects in the respiratory microvasculature, which leads to a decrease in edema and airflow resistance. The ability to decrease intraocular pressure primarily takes place by lowering aqueous production along with a slight effect from inducing vasoconstriction in the conjunctiva. It is worth noting that the alpha agonist often used for this indication, apraclonidine, lowers aqueous production through concurrent alpha-2 effects while vasoconstriction occurs through alpha-1 effects.
FDA approved indications for selected alpha-1 agonists (off-label uses indicated when applicable):
It is worth noting that many agents that are “alpha-1 agonists” have at least some mixed alpha-1 and alpha-2 activity, and others have mixed alpha and beta-agonistic activity.
Adrenergic receptors are G-protein-coupled receptors (GPCR) that play a central role in the sympathetic nervous system. The alpha-1 adrenergic receptors respond to norepinephrine and epinephrine and act through the Gq signaling pathway to facilitate several effects, some specific to the alpha-1 receptor and other effects shared with alpha-2 receptors. When the alpha-1 receptor is activated, the Gq signaling pathway kicks off. This activation leads to phospholipase C activation, and the second messengers, inositol triphosphate (IP3) and diacylglycerol (DAG) cause smooth muscle contraction and glycogenolysis by increasing intracellular calcium. Many of the desired effects of alpha-1 agonists are a result of the vascular smooth muscle contraction resulting in increased systemic vascular resistance, thereby increasing afterload on the heart, which in turn increases blood pressure and decreases cardiac output.
In conditions involving the eyes (such as elevated intraocular pressure, irritation of the eye, or procedures requiring dilation of the pupil), an alpha-1 agonist will most often be administered topically via eye drops. Medications for nasal congestion are often a combination of multiple active agents, and the route of administration will vary from oral tablets or capsules, oral liquid in pediatric patients, nasal sprays for local effect, as seen with oxymetazoline. Epinephrine is given intravenously during CPR and via intramuscular injection during anaphylactic shock.
In general, alpha agonists can cause decreased renal perfusion, increased cardiac afterload, and decreased venous compliance. Phenylephrine, specifically, has documented cases of renal failure. Researchers have also conducted several studies indicating that alpha-1 agonists cause adverse effects on gastrointestinal blood flow due to their inherent vasoconstriction. Epinephrine, while used as an adjunctive to lidocaine injections for local anesthetic effect, has been shown to cause a clinically significant increase in pain when compared to placebo injections.
The suggested general guideline is that each patient’s situation is taken into account when considering the use of alpha-1 agonists. The indications described above often have specific benefits outweighing the potential risks. Still, in general, an alternative vasopressor should be used when possible to avoid adverse effects such as increased cardiac afterload. Catecholamines (norepinephrine and epinephrine) are contraindicated for the treatment of hypotension in the setting of increased serotonin as they can exacerbate the release of serotonin that is already occurring in the underlying disease state. In patients with carcinoid tumors, it is advisable for phenylephrine, octreotide, antihistamines, and hydrocortisone to merit consideration for use instead of a catecholamine.
The monitoring of alpha-1 agonists will depend on the patient’s situation and the drug involved. Patients who are experiencing an anaphylactic reaction will need treatment with epinephrine. Following the cessation of anaphylactic symptoms, the patient must remain under observation for the next six to twelve hours. Current data indicates that 6 hours of observation excludes the occurrence of a secondary reaction in 95% of patients, so the standard of care guidelines require a minimum of 6 hours of observation. Patients who adhere to the dosage recommendations while taking pseudoephedrine, xylometazoline, or oxymetazoline for an upper respiratory infection do not typically require monitoring as long as symptoms improve as expected.
The toxicity of alpha-1 agonists differs between the individual compounds, but specific adverse effects are consistent across the class. Phenylephrine, a prototypical agent, has been used in studies to represent alpha-1 agonistic actions due to its alpha-1 receptor selectivity. Toxicity related to phenylephrine presents as reflex bradycardia, headache, tingling extremities, hypertension, cardiac arrhythmias, and a feeling of fullness in the head. Treatment for an overdose with alpha-1 agonists is mostly supportive, although the application of vasodilators, along with a chronotropic agent, may be beneficial in certain instances. There is no specific antidote for toxicity related to this class of medications.
Alpha-1 agonists have a diverse range of uses, settings, and acuities. Communication between the various members of the interprofessional healthcare team is crucial to ensuring that the patients receive the appropriate dose following an effective timeline. These agents modify vascular smooth muscle contraction and also have powerful positive inotropic effects. Patient-centered care will entail the healthcare provider discerning when a systemic alpha-1 agonist is genuinely a necessity or when an alternative vasopressor could be implemented to avoid the risk of adverse effects. Communication between nurses, pharmacists, and physicians will improve the care for the patients needing alpha-1 agonists and prevent comorbidities. For example, patients with congestive heart failure or chronic renal failure require detailed attention due to their propensity to experience an increase in afterload and renal vasoconstriction more acutely. The pharmacy can ensure dosing and administration is appropriate for the patient/case, and nurses can perform followup to check for therapeutic effectiveness and adverse drug reactions.
During a cardiopulmonary resuscitation (CPR) attempt, there is often a nurse assigned to record the dose and time of each medication administered. One of the main objects of this team member is to call out each time a patient receives a dose of epinephrine, record the time, and then alert the team when it is time for the next dose, should it be required. This communication between the nursing staff administering medications, the physician guiding the resuscitation attempt, and the nurse assigned to record is an example of the clear and coordinated interprofessional care that alpha-1 agonists often require. Proper utilization of these agents requires the dedicated attention of nurses, clinicians, and pharmacists, working as a cohesive interprofessional team, who are well acquainted with the patient's condition and the medications administered. [Level 5]
|||Sacha GL,Bauer SR,Lat I, Vasoactive Agent Use in Septic Shock: Beyond First-Line Recommendations. Pharmacotherapy. 2019 Mar; [PubMed PMID: 30644586]|
|||Soleimani G,Akbarpour M,Mohammadi M, Safety and efficacy of phenylephrine nasal drops in bronchiolitis. Iranian journal of pediatrics. 2014 Oct; [PubMed PMID: 25793067]|
|||Morales J,Brown SM,Abdul-Rahim AS,Crosson CE, Ocular effects of apraclonidine in Horner syndrome. Archives of ophthalmology (Chicago, Ill. : 1960). 2000 Jul; [PubMed PMID: 10900109]|
|||Thiele RH,Nemergut EC,Lynch C 3rd, The clinical implications of isolated alpha(1) adrenergic stimulation. Anesthesia and analgesia. 2011 Aug; [PubMed PMID: 21519053]|
|||Piascik MT,Perez DM, Alpha1-adrenergic receptors: new insights and directions. The Journal of pharmacology and experimental therapeutics. 2001 Aug; [PubMed PMID: 11454900]|
|||Chen ZJ,Minneman KP, Recent progress in alpha1-adrenergic receptor research. Acta pharmacologica Sinica. 2005 Nov; [PubMed PMID: 16225747]|
|||Han JW,Nah SK,Lee SY,Kim CY,Yoon JS,Jang SY, A Prospective, Comparative Study of the Pain of Local Anesthesia Using 2% Lidocaine, 2% Lidocaine With Epinephrine, and 2% Lidocaine With Epinephrine-Bupivicaine Mixture for Eyelid Surgery. Ophthalmic plastic and reconstructive surgery. 2017 Mar/Apr; [PubMed PMID: 26974418]|
|||Kim TH,Yoon SH,Hong H,Kang HR,Cho SH,Lee SY, Duration of Observation for Detecting a Biphasic Reaction in Anaphylaxis: A Meta-Analysis. International archives of allergy and immunology. 2019; [PubMed PMID: 30763927]|
|||Al-Benna S,O'Boyle C,Holley J, Extravasation injuries in adults. ISRN dermatology. 2013; [PubMed PMID: 23738141]|
|||Richards E,Maani CV, Phenylephrine 2019 Jan; [PubMed PMID: 30521222]|
|||Gough CJR,Nolan JP, The role of adrenaline in cardiopulmonary resuscitation. Critical care (London, England). 2018 May 29; [PubMed PMID: 29843791]|